Hims & Hers Health (NYSE:HIMS) Sees Strong Trading Volume Following Analyst Upgrade

Hims & Hers Health, Inc. (NYSE:HIMS) shares saw unusually-high trading volume on Tuesday after Citigroup upgraded the stock from a sell rating to a neutral rating. Citigroup now has a $24.00 price target on the stock, up from their previous price target of $13.25. Approximately 49,826,566 shares were traded during mid-day trading, an increase of 59% from the previous session’s volume of 31,374,480 shares.The stock last traded at $22.9990 and had previously closed at $22.16.

A number of other research firms have also weighed in on HIMS. Leerink Partners cut their target price on shares of Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating on the stock in a research note on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. TD Cowen lowered their price target on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a report on Tuesday, February 24th. Truist Financial reissued a “hold” rating and issued a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $30.46.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the sale, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 23,090 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the sale, the chief financial officer owned 94,333 shares of the company’s stock, valued at $3,369,574.76. This represents a 19.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 80,463 shares of company stock valued at $2,846,696 over the last three months. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Settlement & commercial partnership with Novo Nordisk ends recent patent fight and lets HIMS offer FDA‑approved Wegovy/Ozempic (including new pill formats) on its platform — this materially reduces legal risk and opens a new, high‑margin revenue stream. Read More.
• Positive Sentiment: Multiple analyst upgrades and higher price targets followed the Novo news (Needham to Buy, Citi/Deutsche Bank raised targets/ratings), which supports further upside if GLP‑1 sales ramp. Read More.
• Positive Sentiment: HIMS is expanding its digital‑care platform (new specialties, lab testing, international moves) — a broader service set increases addressable market and cross‑sell opportunities for new branded drug offerings. Read More.
• Neutral Sentiment: Extremely high short interest and recent rapid gains raise the possibility of short‑squeeze‑driven volatility; that can amplify upside but also produce sharp reversals. Monitor short interest and volume closely. Read More.
• Neutral Sentiment: Recent Q4/FY results showed an EPS beat but a slight revenue miss — fundamentals show growth but remain mixed; GLP‑1 revenue could change near‑term guidance if rollout scales. Read More.
• Negative Sentiment: An asset manager has trimmed/left positions, signaling some institutional caution despite the deal — this could limit sustained buying if sentiment cools. Read More.
• Negative Sentiment: A securities‑style investigation into officers and directors was announced earlier this month — while the Novo settlement reduces one legal risk, governance/claims risk remains a headline risk for investors. Read More.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the 1st quarter worth approximately $30,000. Envestnet Asset Management Inc. increased its position in Hims & Hers Health by 41.8% during the second quarter. Envestnet Asset Management Inc. now owns 83,844 shares of the company’s stock worth $4,180,000 after buying an additional 24,726 shares during the period. AE Wealth Management LLC acquired a new position in Hims & Hers Health during the second quarter worth approximately $292,000. Finally, Summit Investment Advisors Inc. lifted its stake in Hims & Hers Health by 187.0% in the first quarter. Summit Investment Advisors Inc. now owns 56,971 shares of the company’s stock valued at $1,683,000 after buying an additional 37,118 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

The firm has a market capitalization of $5.35 billion, a price-to-earnings ratio of 46.01, a P/E/G ratio of 4.24 and a beta of 2.55. The company has a fifty day moving average price of $24.31 and a two-hundred day moving average price of $37.75. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the previous year, the company posted $0.11 EPS. The company’s quarterly revenue was up 28.4% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has initiated a stock buyback program on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.